Meine Merkliste  

3.025 Aktuelle Fachpublikationen von Future Medicine


The agony of the agonists: a review of impulsivity and withdrawal syndromes in Parkinson's disease treatment

14.08.2015 | Andrea J Lindahl; Douglas G MacMahon, Future Neurology, 2015

The introduction of dopamine agonists was a welcome development in the treatment of Parkinson's disease. However, their history has been somewhat checkered with concerns about their side effects including sudden onset of sleep and ‘sleep attacks’ the development of fibrotic side effects with ...


Novel therapeutic strategies for spinal muscular atrophy

14.08.2015 | Omar Khwaja, Future Neurology, 2015

Omar is a pediatric neurologist with specialist skills in critical care, fetal–neonatal neurology and neurogenetics. His research background includes human genetics and neurosciences as well as developmental neurobiology. He also has significant experience in clinical–translational research ...


Interview with Professor Kay Davies

14.08.2015 | Kay Davies, Future Neurology, 2015

Kay Davies is the Dr Lee's Professor of Anatomy in the Department of Physiology, Anatomy and Genetics, and Director of the MRC Functional Genomics Unit at the University of Oxford, UK. Her research interests lie in the molecular analysis and development of treatment for human genetic disease, ...


An update on functional (psychogenic) tremor

14.08.2015 | Mariella Koegl-Wallner; Petra Schwingenschuh, Future Neurology, 2015

Functional tremor accounts for at least 50% of patients with functional movement disorders. The diagnostic work-up of these patients can be challenging. It is a multistep process based on patients’ history and clinical criteria finally providing a ‘positive’ diagnosis. Variability of the tremor ...


How does the oncogene astrocyte elevated gene-1 (AEG-1) augment glioma progression?

14.08.2015 | Luni Emdad; Bin Hu; Timothy P Kegelman; Swadesh K Das; Devanand Sarkar; Paul B Fisher, Future Neurology, 2015

Future Neurology August 2015, Vol. 10, No. 4, Pages 293-296.


Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms

12.08.2015 | Laura R Parham; Linda P Briley; Karen S King; Julie Byrne; Erica Rappold; Paul E Goss; Colin F Spraggs, Pharmacogenomics, 2015

Rash is a common side effect of lapatinib treatment. Since human leukocyte antigen (HLA) alleles have been implicated in multiple drug-induced cutaneous reactions, this study investigated the association of HLA alleles with lapatinib-induced rash. 1191 participants from a large lapatinib ...


Predicting paclitaxel-induced neutropenia using the DMET platform

12.08.2015 | Annemieke JM Nieuweboer; Marcel Smid; Anne-Joy M de Graan; Samira Elbouazzaoui; Peter de Bruijn; John W Martens; Ron ..., Pharmacogenomics, 2015

Aim: The use of paclitaxel in cancer treatment is limited by paclitaxel-induced neutropenia. We investigated the ability of genetic variation in drug-metabolizing enzymes and transporters to predict hematological toxicity. Patients & methods: Using a discovery and validation approach, we ...


Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination

12.08.2015 | Litaty Céphanoée Mbatchi; Antonin Schmitt; Fabienne Thomas; Yoann Cazaubon; Jacques Robert; Serge Lumbroso; Jean-Pau ..., Pharmacogenomics, 2015

Aim: The goal of our study was to assess the impact of patients’ genetic background on their sensitivity to carboplatin/paclitaxel hematotoxicity. Patients & methods: Parameters describing sensitivity to neutropenia and to thrombocytopenia of 201 patients were extracted from a previous ...


Genetic markers of recurrence in colorectal cancer

12.08.2015 | Maria Anna Smolle; Martin Pichler; Johannes Haybaeck; Armin Gerger, Pharmacogenomics, 2015

Colorectal cancer (CRC) worldwide belongs to one of the most frequent cancers affecting both genders. Surgery and 5-fluorouracil-based adjuvant chemotherapy are recommended for patients with high-risk stage II and stage III colon carcinoma. Mutations of genes encoding for specific proteins may ...


Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score

12.08.2015 | Linda M Henricks; Carin ATC Lunenburg; Didier Meulendijks; Hans Gelderblom; Annemieke Cats; Jesse J Swen; Jan HM Sch ..., Pharmacogenomics, 2015

The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a key role in the metabolism of fluoropyrimidines. DPD deficiency occurs in 4–5% of the population and is associated with severe fluoropyrimidine-related toxicity. Several SNPs in DPYD have been described that lead ...


Seite 2 von 303
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.